Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

PR Newswire October 22, 2018

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

PR Newswire October 10, 2018

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

PR Newswire October 4, 2018

Halozyme Therapeutics To Participate In Upcoming Investor Conference

PR Newswire September 20, 2018

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

PR Newswire September 17, 2018

Halozyme Appoints Bernadette Connaughton To Board Of Directors

PR Newswire September 10, 2018

Halozyme Names Benjamin Hickey As Chief Commercial Officer

PR Newswire September 5, 2018

Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 23, 2018

Halozyme Therapeutics To Participate In Upcoming Investor Conferences

PR Newswire August 22, 2018

Halozyme Reports Second Quarter 2018 Results

PR Newswire August 7, 2018

Halozyme Therapeutics To Participate In Upcoming Healthcare Conference

PR Newswire July 26, 2018

Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology

PR Newswire July 26, 2018

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

PR Newswire July 11, 2018

Halozyme To Host Second Quarter 2018 Financial Results Conference Call

PR Newswire July 6, 2018

Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego

PR Newswire June 11, 2018

Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer

PR Newswire June 1, 2018

Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences

PR Newswire May 29, 2018

38 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  May 11, 2018

22 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  May 11, 2018

Halozyme Reports First Quarter 2018 Results

PR Newswire May 10, 2018